Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Oasmia Pharmaceutical AB (publ)
  6. News
  7. Summary
    OASM   SE0000722365

OASMIA PHARMACEUTICAL AB (PUBL)

(OASM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Oasmia Pharmaceutical : to present at Naventus Life Science Summit on September 29

09/24/2021 | 01:00am EST

Solna, Sweden, September 24, 2021 – Oasmia Pharmaceutical’s CEO, Dr Francois Martelet will present at the Naventus Life Science Summit at Grand Hotel in Stockholm on September 29, 2021. The presentation starts at 10:50 CEST and will be live streamed via https://events.naventus.com/.

The event is organized by Naventus Corporate Finance together with Setterwalls, Deloitte, FNCA, Nordnet and Nasdaq.

The presentation will be held in English and will also be available afterwards on Oasmia Pharmaceutical’s website www.oasmia.com

For More Information: 

Oasmia Pharmaceutical AB 
Francois Martelet, Chief Executive Officer 
Phone: +46 18-50 54 40 
E-mail: IR@oasmia.com

Consilium Strategic Communications 
Jonathan Birt, Chris Welsh, Ashley Tapp
Phone: +44 (0)20 3709 5700 
E-mail: oasmia@consilium-comms.com


About Oasmia Pharmaceutical AB
Oasmia is a specialty pharmaceutical company focused on the development of new therapeutic options for patients suffering from hard-to-treat cancers. It has an emerging pipeline of clinical-stage assets targeting late-stage cancers. Apealea® (paclitaxel micellar) is being made available to ovarian cancer patients through a partnership with Elevar Therapeutics, Inc. Development programs include Cantrixil, in clinical development for late-stage ovarian cancer, and docetaxel micellar, in development for advanced prostate cancer. Oasmia has proprietary drug delivery technology designed to improve solubility, efficacy and safety. Oasmia’s shares are traded on Nasdaq Stockholm (OASM). To find out more about Oasmia please visit www.oasmia.com.

© Modular Finance, source Nordic Press Releases

All news about OASMIA PHARMACEUTICAL AB (PUBL)
11/26Oasmia to present at the Erik Penser Bank Life Science Day on December 2
AQ
11/26Oasmia to present at Stora Aktiedagen Stockholm on December 2
AQ
11/18Oasmia Pharmaceutical AB Reports Earnings Results for the Third Quarter and Nine Months..
CI
11/12Invitation to presentation of Oasmia's Q3 report on November 18
AQ
11/11Invitation to presentation of Oasmia's Q3 report on November 18
AQ
10/21OASMIA PHARMACEUTICAL : announces global settlement of all disputes with MGC Capital, form..
AQ
10/20OASMIA PHARMACEUTICAL : Bulletin from Extraordinary General Meeting in Oasmia Pharmaceutic..
AQ
10/01OASMIA PHARMACEUTICAL : Naventus LifeScience Summit
PU
09/24OASMIA PHARMACEUTICAL : to present at Naventus Life Science Summit on September 29
AQ
09/20OASMIA PHARMACEUTICAL : Notice of Extraordinary General Meeting in Oasmia Pharmaceutical A..
AQ
More news
Financials
Sales 2021 10,2 M 1,11 M 1,11 M
Net income 2021 -173 M -18,9 M -18,9 M
Net cash 2021 130 M 14,2 M 14,2 M
P/E ratio 2021 -5,35x
Yield 2021 -
Capitalization 959 M 105 M 105 M
EV / Sales 2021 81,3x
EV / Sales 2022 23,8x
Nbr of Employees 26
Free-Float 61,3%
Chart OASMIA PHARMACEUTICAL AB (PUBL)
Duration : Period :
Oasmia Pharmaceutical AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OASMIA PHARMACEUTICAL AB (PUBL)
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 0
Last Close Price 2,14 SEK
Average target price 5,70 SEK
Spread / Average Target 167%
EPS Revisions
Managers and Directors
Franšois R. Martelet Chief Executive Officer
Fredrik Jńrrsten Chief Financial Officer
Karl Anders Olof Hńrfstrand Independent Non-Executive Chairman
Heidi B. Ramstad Chief Medical Officer
Reinhard Koenig Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
OASMIA PHARMACEUTICAL AB (PUBL)-48.11%105
JOHNSON & JOHNSON1.82%419 109
ROCHE HOLDING AG16.05%336 162
PFIZER, INC.46.70%303 095
NOVO NORDISK A/S67.00%247 254
ELI LILLY AND COMPANY54.21%236 049